SCHEMBL9633293

SCHEMBL9633293

Cc1nccc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
LMNA P02545 2/20 0.59
MAPT P10636 6/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
KMO O15229 1/20 0.54
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
MAP4K4 O95819 1/20 0.50
KDM1A O60341 1/20 0.49
MAOA P21397 1/20 0.49
HPGD P15428 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PIK3CG P48736 3/20 0.48
PIK3CA P42336 2/20 0.48
PIK3CB P42338 2/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
CYP1A2 P05177 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30885726 1.00 KDM4E (0.59) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL10194257 0.83 KDM4E (0.62) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL2406207 0.82 KDM4E (0.49) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL27115085 0.80 MEN1 (0.66) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL2404944 0.80 KDM4E (0.59) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL21537437 0.80 KDM4E (0.59) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL2016844 0.80 KDM4E (0.59) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL18119036 0.80 KDM4E (0.59) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL21873613 0.79 KDM4E (0.54) KDM4ELMNAMAPTMEN1KMT2A
SCHEMBL2402821 0.79 KMO (0.65) KDM4ELMNAMAPTKMOALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0516278-A1 Use of anti-mullerian hormone for reversal of female sexual phenotype in poultry MERCK & CO. INC. (US) 1992-12-02 EP claimed
EP-0514015-A1 Control of sex differentiation in fish MERCK & CO. INC. (US) 1992-11-19 EP claimed
US-5162337-A Administering Steroid Biosynthesis Inhibitors MERCK & CO., INC. (US) 1992-11-10 US claimed
WO-1992018132-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR MERCK & CO., INC. (US) 1992-10-29 WO claimed
EP-0479570-A2 Animal growth promotion with aromatase inhibitors MERCK & CO. INC. (US) 1992-04-08 EP claimed
EP-0433084-A2 Use of aromatese inhibitors for the reversal of female sexual phenotype in poultry MERCK & CO. INC. (US) 1991-06-19 EP claimed
US-8785445-B2 7-phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC. (US) 2014-07-22 US disclosed
WO-2010075200-A1 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2010-07-01 WO disclosed
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-27 US disclosed
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-27 US disclosed
WO-2007034251-A1 AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2007-03-29 WO disclosed
EP-0516278-A1 Use of anti-mullerian hormone for reversal of female sexual phenotype in poultry MERCK & CO. INC. (US) 1992-12-02 EP disclosed
EP-0514015-A1 Control of sex differentiation in fish MERCK & CO. INC. (US) 1992-11-19 EP disclosed
US-5162337-A Administering Steroid Biosynthesis Inhibitors MERCK & CO., INC. (US) 1992-11-10 US disclosed
EP-0479570-A2 Animal growth promotion with aromatase inhibitors MERCK & CO. INC. (US) 1992-04-08 EP disclosed
EP-0433084-A2 Use of aromatese inhibitors for the reversal of female sexual phenotype in poultry MERCK & CO. INC. (US) 1991-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands CCR3, CCR1, CCR4 KDM4E 3442/4885LMNA 3402/4885MAPT 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.